Stock Upgrades Today See Wall Street Boost Confidence

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  13 Nov 2025
 

•   ACHC  
   
  -0.25%
•   AEIS  
   
  +1.10%
•   ALC  
   
  -0.64%
•   AMD  
   
  +0.13%
•   ANRO  
   
  -8.62%

$ACHC opens the day with a confident nod from RBC Capital, which maintained its Outperform rating and sees more than 70% upside ahead. For a healthcare operator navigating demand tailwinds, that’s a vote of confidence worth noting.

$AEIS gets a Buy reiteration from Citigroup, though the forecasted downside suggests the call is more about long-term positioning than immediate upside. Mixed signals, but still a supportive stance.

$ALC enjoys a reaffirmed Buy from Needham, pointing to more than 35% potential upside. With stable demand across its vision-care portfolio, the bullish stance feels aligned with broader sector momentum.

$AMD receives a flood of confidence as multiple firms including BofA, Mizuho, Evercore ISI, Wedbush, Rosenblatt, and Roth Capital all reiterate Buy or Outperform ratings. The price target implies modest downside, but the sheer volume of bullish reiterations makes one thing clear: analysts still see AMD as a leadership anchor in the semiconductor cycle.

$ANRO gains a Buy from Jefferies, with upside potential north of 34%. Alto Neuroscience remains an early-stage, high-variance name, but the endorsement adds credibility to its pipeline narrative.

$ARM secures a Buy from Loop Capital with modest upside. With AI-driven licensing demand still rising, Arm continues to attract patient bullishness.

$ASTS gets a Buy from Clear Street despite a forecasted downside one of those situations where long-term vision outweighs short-term valuation math. Satellite-to-phone plays carry big hopes and big risks.

$BA stays in the spotlight with a Positive rating by Susquehanna and a projected 34% upside. Boeing’s turnaround story is slow, but every reaffirmation supports the multi-year recovery case.

$BTDR stands out with a massive upside estimate above 135% from B. Riley. High-beta, high-conviction classic crypto-infra volatility meets bullish analyst enthusiasm.

$BTE earns an upgrade from BMO following its Eagle Ford divestiture, a reminder that strategic reshuffling can reignite confidence even in traditional energy names.

$BWAY gets an Outperform from Northland, though the price forecast warns of substantial downside. A rare case where rating and valuation aren’t telling the same story.

$CAPR receives a Buy from Roth Capital with staggering upside potential over 250%. Small-cap biotech meets high-expectation territory where catalysts matter more than charts.

$CHRD maintains a Buy from UBS and shows over 50% upside potential, reflecting strong confidence in energy cash flow durability.

$CIVI keeps its Outperform from Mizuho with near 51% upside. Another energy name riding structural discipline and favorable margins.

$CMPO gets upgraded by JPMorgan from Underweight to Neutral, signaling that sentiment may be shifting after a period of underperformance.

$CNTY receives a Buy from Stifel with dramatic upside potential of 125%. Casino operators often move in cycles, and analysts seem to believe this one is preparing its next leg up.

$COYA stays in the Buy camp with reinforcement from D. Boral Capital and nearly 171% projected upside. Experimental therapeutics mean high volatility but also high intrigue.

$CRMD lands two Buy reiterations, signaling conviction in its upcoming milestones with upside north of 70%.

$CRWV gains a Buy from Loop Capital and nearly 67% upside potential as CoreWeave continues scaling its AI-hardware infrastructure story.

$CSWC is upgraded to Buy by Clear Street following strong quarterly results, underscoring both business momentum and dividend appeal.

$DDOG holds its Buy from Citigroup even as the target suggests downside a classic case of premium valuation for a premium software operator.

$DOC receives an Outperform from Baird with around 20% upside, giving healthcare-real-estate investors something to watch.

$DOX keeps its Buy from Stifel with nearly 38% upside. As digital infrastructure demand expands, Amdocs remains a steady compounder.

$ENGN receives bullish support from both Oppenheimer and Citizens, each expecting over 150% upside strong enthusiasm for this emerging biotech.

$EVH stands out with nearly 260% upside potential following Oppenheimer’s Outperform reiteration, positioning it as one of today’s more explosive calls.

$EWCZ maintains Market Perform from Telsey but still shows a surprising 62% upside, making it a valuation-to-performance mismatch worth watching.

$FAST gets Underperform from Bernstein, though the target suggests slight upside. A cautious stance despite modestly improving expectations.

$FERG receives Outperform coverage with mild upside, keeping sentiment stable for this industrial distributor.

$HQI maintains Outperform from Barrington with nearly 46% upside a quiet but steady name in staffing and labor solutions.

$HTGC is upgraded by Compass Point on strong results, reinforcing its reputation as a resilient income-oriented BDC.

$HUMA skyrockets in analyst expectations as D. Boral Capital maintains a Buy with extraordinary upside above 590%. One of the highest conviction calls of the day.

$LAR maintains Sector Perform with about 19% upside as lithium markets continue recalibrating.

$LINE holds Sector Perform from Scotiabank with over 46% upside, reflecting cautious optimism in logistics and cold-storage trends.

$LLY keeps its Buy rating but with slight downside expected a reminder that mega-cap pharma often trades ahead of fundamentals.

$LPTH receives dual Buy reiterations with nearly 20% upside, supporting sentiment for this optical-tech small-cap.

$LRCX keeps its Buy from Citigroup with flat-to-slight downside, but long-term positioning in chip-equipment remains strong.

$MOS gets repeated Buy ratings from Goldman, with upside above 50% as fertilizer cycles begin turning more constructive.

$NGS secures a Buy with over 24% projected upside steady industrial momentum continues to attract analyst attention.

$NKE receives an upgrade as Wells Fargo sees improving fundamentals and 17% upside ahead.

$NUVL gains a Buy from Canaccord with 25% upside, keeping biotech sentiment alive.

$NWN maintains Buy with moderate upside, fitting its identity as a slow-and-steady utility.

$OKLO receives mixed but generally positive reinforcement with Buy/Outperform ratings, despite mild downside in forecasts.

$OUT gets an upgrade to Overweight from JPMorgan, though the price target leans defensive an interesting contrast for this media-ad player.

$PAL holds its Outperform rating with over 51% upside as analyst enthusiasm remains strong for the logistics provider.

$PGNY is upgraded to Overweight, supported by nearly 22% upside and continued leadership in fertility-benefits services.

$PH maintains positive sentiment across multiple analysts despite a slight downside target a reflection of its reputation as an industrial powerhouse.

$PRKS carries an Underperform rating but surprisingly shows huge estimated upside. A mixed signal that demands deeper digging.

$PRVA keeps its Buy rating with nearly 33% upside as healthcare-services growth continues.

$RDNT maintains Buy with moderate upside, sustaining confidence in its imaging-care expansion.

$ROL receives Outperform initiation with slight upside, pointing to stable, predictable growth ahead.

$SLI remains in Buy territory with nearly 25% upside as lithium markets stabilize.

$STXS stays a Buy with almost 82% upside, reflecting bullishness on precision-cardiac robotics.

$T gets upgraded to Overweight with 17% upside potential a notable shift for a telecom giant often viewed as slow-moving.

$TER holds its Buy rating despite downside expectations, suggesting analysts see longer-term strength beyond current valuation concerns.

$TS keeps its Buy rating with slight upside, aligned with stable energy-equipment demand.

$VKTX receives a Buy with more than 130% upside one of the more aggressive biotech calls today.

$VYGR wins a Buy reaffirmation with over 275% upside potential, putting it firmly in high-reward territory.

$W keeps its Outperform rating despite downside targets a reminder of just how volatile e-commerce names can be.

$WULF remains a Buy with over 26% upside, as crypto-mining plays stay highly momentum-driven.

View All Headlines